|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
The promising data sent shares soaring Tuesday; here's what investors need to know now.
Shares rise 15.9% after the company completed the initial portion of the Goliad ISR Uranium Project.
The Elan and Wyeth drug was at least partially effective in a subgroup of patients lacking a higher genetic risk for developing Alzheimer's.
The potential market for bapineuzumab is massive. Here's how to sort the trial data when released.
Uncertain regulation hangs on Vertex's telaprevir, The Medicines Co. remains mum on Cleviprex and a summer biotech-stock watch list.
A second phase III study of Fampridine-SR shows the drug improves walking in multiple sclerosis patients.
Here are some of the stocks the 'Fast Money' crew has been talking about lately.
The way the biotech structured a licensing deal with Lundbeck for the late-stage Alzheimer's drug may protect both in a way.
Lundbeck A/S will pay as much as $350 million for European rights to the late-stage Alzheimer's drug.
Elan's investor meeting proves exclusive; Medarex and the FDA, and more.
Fooling Some People All of the Time is a must-read for investors.
Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.
The biotech company posts first-quarter profit and revenue that just exceed expectations.
Sales of the biotech company's Avonex exceed Wall Street targets in the first quarter.
Glaxo may face a tough sell with newly approved Treximet; additional feedback on Elan, and more.
Incidence of a skin lesion prompts the suspension of a phase II trial for their experimental vaccine ACC-001.
Pozen Pharma climbs on news of regulatory approval for migraine drug Treximet.
Patient use of the multiple sclerosis drug makes a 25% quarter-over-quarter rise.
The latest M&A and what it means more broadly; tapping Russia for drug approvals; the next potential insulin play and more.
A high-profile paper published last year failed to disclose that one of the co-authors had financial ties to the drugmakers.
Avastin's approval could spark Genentech to boost earnings guidance.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.